熱門資訊> 正文
移植疗法首次商业销售后，Omeros走高
2026-01-28 01:38
- Shares of Omeros Corporation (OMER) gained on Tuesday after the company announced first commercial shipments of Yartemlea, its recently approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy, a complication of stem cell transplantation.
- The Seattle, Washington-based biotech received FDA approval in December to market Yartemlea for patients aged two years and above with TA-TMA. A condition linked to hematopoietic stem cell transplantation, TA-TMA, has a more than 90% mortality rate in severe cases.
- Omeros (OMER) stated that the first commercial shipments of Yartemlea began last week, and concurrently, it fulfilled initial orders for the drug received from multiple transplant centers.
- Adults and children with TA-TMA are now undergoing Yartemlea therapy, including those who have failed prior off-label C5-inhibitor regimens in both inpatient and outpatient-based care settings, the company added.
More on Omeros
- Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
- Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)
- Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid
- Omeros surges on FDA nod for transplant therapy (update)
- Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart
推薦文章
華盛早報 | 特朗普再發驚人言論！美元跌至四年低谷，金價續創新高；聯合健康績后重挫近20%
1月28日外盤頭條：美元跌至四年低點 特朗普稱不擔心 谷歌推出低價版AI Plus 特朗普關税落地概率不足三成
美股機會日報 | 美光擬豪擲240億美元擴產存儲芯片！聯合健康遭雙重利空打擊，盤前暴跌15%
再出手飆漲超60%！特朗普政府重金入股美稀土公司，這份「關鍵礦產公司名單」請收好
華盛早報 | 特朗普突發貿易威脅！對韓國加税至25%；白銀「深V」閃崩后又急升
新股申購 | 國恩科技今起招股！一手入場費8484.71港元
特朗普政府16億美元入股美國稀土公司，佈局稀土供應鏈
摩根士丹利和美銀看好新興市場套利交易 去年回報已創2009年以來最強
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
